Amphastar Pharma (AMPH) Misses Q4 EPS by 20c

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.73, $0.20 worse than the analyst estimate of $0.93. Revenue for the quarter came in at $183.1 million versus the consensus estimate of $191.76 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• Daimler Truck Holding AG (DTG:GR) (DTRUY) PT Raised to EUR37 at Bernstein SocGen Group
• NorthStar and Viking file F-4 for $300M SPAC merger